Implications of central immune signaling caused by drugs of abuse: mechanisms, mediators and new therapeutic approaches for prediction and treatment of drug dependence.
- J. Coller, M. Hutchinson
- Biology, MedicinePharmacology and Therapeutics
- 1 May 2012
Pharmacogenetics of Opioids
- A. Somogyi, D. Barratt, J. Coller
- Biology, MedicineClinical pharmacology and therapy
- 1 March 2007
The role of pharmacogenomics in mediating interpatient variability in efficacy and side effects to this important class of drugs will be better informed as knowledge regarding the interplay between genes affecting opioid pharmacokinetics including cerebral kinetics and pharmacodynamics increases.
Inhibiting the TLR4‐MyD88 signalling cascade by genetic or pharmacological strategies reduces acute alcohol‐induced sedation and motor impairment in mice
- Yue Wu, Erin L. Lousberg, M. Hutchinson
- MedicineBritish Journal of Pharmacology
- 1 March 2012
Whether TLR4–MyD88‐dependent signalling is involved in the acute behavioural actions of alcohol and if alcohol can activateTLR4‐downstream MAPK and NF‐κB pathways is determined.
The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver.
- J. Coller, N. Krebsfaenger, T. Mürdter
- Biology, MedicineBritish Journal of Clinical Pharmacology
- 1 August 2002
CYP2B6, CYP2C9 and CYP 2D6 genotypes all affected Z-4-hydroxy-tamoxifen formation and can predict individual ability to catalyse this reaction, as well as predicting the effect of chemical and monoclonal antibody inhibitors.
CYP2D6 and CYP3A4 involvement in the primary oxidative metabolism of hydrocodone by human liver microsomes.
- M. Hutchinson, A. Menelaou, D. Foster, J. Coller, A. Somogyi
- Biology, MedicineBritish Journal of Clinical Pharmacology
- 27 November 2003
The O-demethylation of hydrocodone is predominantly catalyzed by CYP2D6 and to a lesser extent by an unknown low affinity cytochrome p450 enzyme, and the genetic polymorphisms of CYP 2D6 may influence hydromorphone metabolism and its therapeutic efficacy.
ABCB1 genetic variability and methadone dosage requirements in opioid‐dependent individuals
- J. Coller, D. Barratt, K. Dahlen, Morten H. Loennechen, A. Somogyi
- PsychologyClinical pharmacology and therapy
- 1 December 2006
Attenuation of microglial and IL-1 signaling protects mice from acute alcohol-induced sedation and/or motor impairment
- Yue Wu, Erin L. Lousberg, M. Hutchinson
- Medicine, BiologyBrain, behavior, and immunity
- 1 June 2011
Role of active metabolites in the use of opioids
- J. Coller, L. Christrup, A. Somogyi
- Biology, MedicineEuropean Journal of Clinical Pharmacology
- 1 February 2009
Clinicians need to be aware that many opioids have active metabolites that will become therapeutically important, for example in cases of altered pathology, drug interactions and genetic polymorphisms of drug-metabolizing enzymes.
The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro
- Yibai Li, J. Coller, A. Somogyi
- Biology, ChemistryDrug Metabolism And Disposition
- 1 June 2013
Results indicate a major role of CYP2B6 in ketamine N-demethylation in vitro and a significant impact of the CYP 2B6*6 allele on enzyme-ketamine binding and catalytic activity.
Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments
- D. Barratt, J. Coller, A. Somogyi
- BiologyAmerican Journal of Medical Genetics Part B…
- 5 June 2006
The need for a further prospective investigation into the role of the DRD2 A1 allele in heroin use and response to maintenance pharmacotherapies for opioid dependence is suggested.
...
...